Lipidemia Clinical Trials

2 recruiting

Lipidemia Trials at a Glance

114 actively recruiting trials for lipidemia are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Not Applicable with 47 trials, with the heaviest enrollment activity in Seoul, Beijing, and Beijing. Lead sponsors running lipidemia studies include University of Georgia, NewAmsterdam Pharma, and Chang Gung Memorial Hospital.

Treatments under study

About Lipidemia Clinical Trials

Looking for clinical trials for Lipidemia? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lipidemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lipidemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 114 trials

Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Healthy ParticipantsDyslipidemia
AstraZeneca136 enrolled6 locationsNCT06980428
Recruiting
Phase 3

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Hyperlipidemia
Merck Sharp & Dohme LLC975 enrolled89 locationsNCT07216482
Recruiting

Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa

ObesityCardiovascular DiseasesChronic Kidney Diseases+8 more
Swiss Tropical & Public Health Institute1,200 enrolled1 locationNCT05881447
Recruiting
Not Applicable

Goal Commitment and Proactive Health Behavior in Chronic Disease Patients

Diabetes MellitusHypertensionDyslipidemia
Xiong Juyang600 enrolled1 locationNCT07552571
Recruiting
Phase 1

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

HypercholesterolemiaHypertriglyceridemiaRefractory Hyperlipidemia
Verve Therapeutics, Inc.36 enrolled10 locationsNCT06451770
Recruiting
Not Applicable

A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

Diabetes MellitusObesityHypertension+2 more
University of Connecticut72 enrolled3 locationsNCT07238556
Recruiting
Not Applicable

Group Medical Visits for Patients With Dyslipidemia

Dyslipidemias
Université de Sherbrooke288 enrolled1 locationNCT07543718
Recruiting

The Bialystok Bariatric Surgery Study

Diabetes MellitusObesityMetabolic Syndrome+1 more
Medical University of Bialystok1,000 enrolled1 locationNCT04634591
Recruiting
Phase 2

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Dyslipidemias
NewAmsterdam Pharma69 enrolled1 locationNCT06496243
Recruiting

Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study

Dyslipidemias
JW Pharmaceutical10,000 enrolled1 locationNCT07523971
Recruiting
Phase 3

A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia

Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.760 enrolled2 locationsNCT07421297
Recruiting
Not Applicable

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

PrehypertensionBorderline Dyslipidemia
Beijing Anzhen Hospital1,400 enrolled3 locationsNCT07372729
Recruiting

Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions

AtherosclerosisDyslipidemia
National Heart, Lung, and Blood Institute (NHLBI)1,500 enrolled1 locationNCT06676046
Recruiting
Not Applicable

Mechanism of Ketogenic Diet-Induced Hypercholesterolemia

Hypercholesterolemia and Hyperlipidemia
Washington University School of Medicine100 enrolled1 locationNCT06894004
Recruiting
Phase 1

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

HypercholesterolaemiaMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG90 enrolled18 locationsNCT07491172
Recruiting
Not Applicable

Penn Medicine Healthy Heart

HypertensionHyperlipidemias
University of Pennsylvania1,980 enrolled1 locationNCT06062394
Recruiting
Phase 2

Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

Dyslipidemias
Ribocure Pharmaceuticals AB120 enrolled4 locationsNCT06797401
Recruiting
Not Applicable

Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)

Dyslipidemia Associated With Type II Diabetes Mellitus
Sin Gon Kim2,186 enrolled2 locationsNCT07359105
Recruiting
Phase 3

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Type 2 Diabetes (T2DM)LipidemiaMetabolic Syndrome (MetS)
NewAmsterdam Pharma300 enrolled20 locationsNCT07219602
Recruiting
Not Applicable

'Ai Pono Cooking Demonstrations

HypertensionType 2 DiabetesOverweight and Obesity+1 more
University of Hawaii1,780 enrolled2 locationsNCT06526650